Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
3 August 2020
The Pathologist reports on research, innovations, personalities, and policies that shape pathology. Each year The Pathologist celebrates 100 inspirational and influential professionals in laboratory medicine.
Professor Scolyer has been recognised in the Big Breakthroughs category, due to his cutting-edge research discoveries that have changed clinical and pathology practice worldwide. He is a leader in determining mechanisms of enhanced response versus resistance to drugs in development, such as immunotherapies – data that underpins the design of current clinical trials.
A world leader in melanoma pathology, Professor Scolyer provides a clinical consultation service for the diagnosis of difficult pigmented lesions, receiving over 2,000 cases from around the world each year.
“My biggest influence has been the Melanoma Institute Australia Research Database that was set up by the late Gerry Milton 60 years ago,” Professor Scolyer says. “This is now the largest melanoma patient database in the world, with over 50,000 patients, and is a major international resource that has provided me with many opportunities to perform important research that correlates pathological and clinical features with patient outcome data in large cohorts.
“Whatever you do, make sure you enjoy the process – because it’s through passion and fulfilment that you will have success and achieve things,”
And Professor Scolyer’s biggest wish? “That people of all ages, but especially young people, were more vigilant in protecting themselves from the sun. UV exposure leading to sunburn is the single biggest risk factor for developing melanoma, which claims one Australian life every five hours.”
See the full 2020 Power List here: https://thepathologist.com/power-list/2020
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.